Medicare Director Meena Seshamani on CMS’ New Drug Pricing Powers
Medicare director Meena Seshamani discusses her team’s sprint to put historic drug price reforms into action.
Read MoreMedicare director Meena Seshamani discusses her team’s sprint to put historic drug price reforms into action.
Read MoreIn 2023 states will pursue new abortion laws, restart Medicaid eligibility checks and Medicare begins to flex its new power to negotiate drug prices.
Read MoreMore than $50 billion in opioid settlement dollars from drugmakers, distributors and pharmacies are starting to flow to state and local governments.
Read More‘Local Officials Grapple With How to Spend Opioid Settlement Dollars’ Transcript November 17, 2022 Note: This transcript has been created with a combination of machine ears and human eyes. There may be small differences between this document and the audio version, which is one of many reasons we encourage you to listen to the episode! Listen…
Read More‘Medicare’s Prescription Drug Plan Makeover’ Transcript October 27, 2022 Note: This transcript has been created with a combination of machine ears and human eyes. There may be small differences between this document and the audio version, which is one of many reasons we encourage you to listen to the episode! Listen in Apple Podcasts Listen on Spotify…
Read MoreAn overhaul of Medicare’s prescription drug benefit will lower costs for seniors while changing incentives for insurers and drugmakers.
Read MoreCongress gave Medicare historic new powers to lower drug prices, but lawsuits, loopholes and opposition from the drug industry could undermine them.
Read MoreStacie Dusetzina shares key takeaways from the drug pricing provisions of the new Inflation Reduction Act.
Read More